WE CLAIM:

1. Use of a compound of formula (I), or a tautomer, or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for use in a method for activating Yes-associated protein 1 (YAP) in a subject in need thereof:



(I)

wherein

ring 

is selected from the group consisting of:



, and ;

R is selected from H and C_1-C_6-alkyl;

R^1 is selected from the group consisting of C_6-C_{10}-aryl, 5- to 10-membered heteroaryl (wherein 1-4 heteroaryl members are independently selected from N, O, and S),

R^2, when present, is selected from the group consisting of H, C_6-C_{10}-aryl, 5- to 10-membered heteroaryl (wherein 1-4 heteroaryl members are independently selected from N, O, and S),

or R^1 and R^2, when bound to adjacent atoms, together with the atoms to which they are bound, form a fused C_6-C_{10}-aryl or 5- to 10-membered heteroaryl (wherein 1-4 heteroaryl members are independently selected from N, O, and S);

L is C(O), C(S), or CH_2;

V is NR^3R^4, wherein

R^3 is selected from the group consisting of C_1-C_6-alkyl, -(C_1-C_6-alkyl)-S-(C_1-C_6-alkyl), -C_1-C_6-alkyl-(C_6-C_{10}-aryl), -C_1-C_6-alkyl-(5- to 10-membered heteroaryl

(wherein 1-4 heteroaryl members are independently selected from N, O, and S)), C_3-C_{14}-cycloalkyl, 3- to 14-membered heterocycloalkyl (wherein 1-4 heterocycloalkyl ring members are independently selected from N, O, and S), -C_1-C_6-alkyl-(3- to 14-membered heterocycloalkyl (wherein 1-4 heterocycloalkyl ring members are independently selected from N, O, and S)),

R^4 is selected from the group consisting of H, C_1-C_6-alkyl, -C_1-C_6-alkyl-(C_6-C_{10}-aryl), 5- to 10-membered heteroaryl (wherein 1-4 heteroaryl members are independently selected from N, O, and S);

or R^3 and R^4, together with the N atom to which they are bound, form a 5- to 7-membered heterocycloalkyl optionally fused or spirofused to a (3- to 14-membered heterocycloalkyl (wherein 1-4 heterocycloalkyl ring members are independently selected from N, O, and S);

and wherein any alkyl, aryl, cycloalkyl, heteroaryl, and heterocycloalkyl is optionally substituted by one to four substituents independently selected from the group consisting of -CN, -OH, halo, oxo, -OR^A, -SR^A, -$S(O)R^A$, -$S(O)_2R^A$, NR^AR^B, -$C(O)R^A$, -$C(O)_2R^A$, -$NR^AC(O)_2R^B$, -$C(O)NR^AR^B$, -$S(O)NR^AR^B$, -$S(O)_2NR^AR^B$, -$NR^AS(O)R^B$, -$NR^AS(O)_2R^B$, 5- to 10-membered heteroaryl (wherein 1-4 heteroaryl members are independently selected from N, O, and S;

R^A and R^B are independently selected from the group consisting of H, C_1-C_6-alkyl, C_1-C_6-haloalkyl, -C_1-C_6-alkyl-C_6-C_{10}-aryl, $C(O)C_1$-C_6-alkyl, $C(O)C_1$-C_6-alkyl-C_6-C_{10}-aryl, $C(O)OC_1$-C_6-alkyl, C_6-C_{10}-aryl, 3- to 14-membered heterocycloalkyl (wherein 1-4 heterocycloalkyl ring members are independently selected from N, O, and S), -C(O)(5- to 10-membered heteroaryl (wherein 1-4 heteroaryl members are independently selected from N, O, and S), wherein

each aryl and heterocycloalkyl is optionally substituted with one to three substituents independently selected from C_1-C_6-alkyl, halo, C_1-C_6-haloalkyl, and 3- to 14-membered heterocycloalkyl (wherein 1-4 ring members are independently selected from N, O, and S); and

each alkyl is optionally substituted with one to three substituents independently selected from halo, NR^CR^D (wherein R^C and R^D are

independently selected from H, C_1-C_6-alkyl, C(O)C_1-C_6-alkyl, and C(O)C_6-C_{10}-aryl)

wherein the compound of formula (I), or a tautomer, or a pharmaceutically acceptable salt thereof is to be administered to the subject.

2. Use of a compound of formula (I), or a tautomer, or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment of a disease or condition whose etiology is exacerbated or defined by insufficient proliferative repair in a subject suffering therefrom, or that is ameliorated by induced proliferation of cells:


(I)

wherein

ring  is selected from the group consisting of:



R is selected from H and C_1-C_6-alkyl;

R^1 is selected from the group consisting of C_6-C_{10}-aryl, 5- to 10-membered heteroaryl (wherein 1-4 heteroaryl members are independently selected from N, O, and S),

R^2, when present, is selected from the group consisting of H, C_6-C_{10}-aryl, 5- to 10-membered heteroaryl (wherein 1-4 heteroaryl members are independently selected from N, O, and S),

or R^1 and R^2, when bound to adjacent atoms, together with the atoms to which they are bound, form a fused C_6-C_{10}-aryl or 5- to 10-membered heteroaryl (wherein 1-4 heteroaryl members are independently selected from N, O, and S);

L is C(O), C(S), or CH_2;

V is NR^3R^4, wherein

R^3 is selected from the group consisting of C_1-C_6-alkyl, -(C_1-C_6-alkyl)-S-(C_1-C_6-alkyl), -C_1-C_6-alkyl-(C_6-C_{10}-aryl), -C_1-C_6-alkyl-(5- to 10-membered heteroaryl (wherein 1-4 heteroaryl members are independently selected from N, O, and S)), C_3-C_{14}-cycloalkyl, 3- to 14-membered heterocycloalkyl (wherein 1-4 heterocycloalkyl ring members are independently selected from N, O, and S), -C_1-C_6-alkyl-(3- to 14-membered heterocycloalkyl (wherein 1-4 heterocycloalkyl ring members are independently selected from N, O, and S)),

R^4 is selected from the group consisting of H, C_1-C_6-alkyl, -C_1-C_6-alkyl-(C_6-C_{10}-aryl), 5- to 10-membered heteroaryl (wherein 1-4 heteroaryl members are independently selected from N, O, and S);

or R^3 and R^4, together with the N atom to which they are bound, form a 5- to 7-membered heterocycloalkyl optionally fused or spirofused to a (3- to 14-membered heterocycloalkyl (wherein 1-4 heterocycloalkyl ring members are independently selected from N, O, and S);

and wherein any alkyl, aryl, cycloalkyl, heteroaryl, and heterocycloalkyl is optionally substituted by one to four substituents independently selected from the group consisting of -CN, -OH, halo, oxo, -OR^A, -SR^A, -$S(O)R^A$, -$S(O)_2R^A$, NR^AR^B, -$C(O)R^A$, -$C(O)_2R^A$, -$NR^AC(O)_2R^B$, -$C(O)NR^AR^B$, -$S(O)NR^AR^B$, -$S(O)_2NR^AR^B$, -$NR^AS(O)R^B$, -$NR^AS(O)_2R^B$, 5- to 10-membered heteroaryl (wherein 1-4 heteroaryl members are independently selected from N, O, and S

R^A and R^B are independently selected from the group consisting of H, C_1-C_6-alkyl, C_1-C_6-haloalkyl, -C_1-C_6-alkyl-C_6-C_{10}-aryl, $C(O)C_1$-C_6-alkyl, $C(O)C_1$-C_6-alkyl-C_6-C_{10}-aryl, $C(O)OC_1$-C_6-alkyl, C_6-C_{10}-aryl, 3- to 14-membered heterocycloalkyl (wherein 1-4 heterocycloalkyl ring members are independently selected from N, O, and S), -C(O)(5- to 10-membered heteroaryl (wherein 1-4 heteroaryl members are independently selected from N, O, and S), wherein

each aryl and heterocycloalkyl is optionally substituted with one to three substituents independently selected from C_1-C_6-alkyl, halo, C_1-C_6-haloalkyl, and 3- to 14-membered heterocycloalkyl (wherein 1-4 ring members are independently selected from N, O, and S); and

each alkyl is optionally substituted with one to three substituents independently selected from halo, NR^CR^D (wherein R^C and R^D are independently selected from H, C_1-C_6-alkyl, $C(O)C_1$-C_6-alkyl, and $C(O)C_6$-C_{10}-aryl)

wherein the compound of formula (I), or a tautomer, or a pharmaceutically acceptable salt thereof is to be administered to the subject.

3. The use according to claim 1 or 2, wherein L is C(O).

4. The use according to any one of claims 1 to 3, wherein R^3 is optionally substituted C_1-C_6-alkyl or -C_1-C_6-alkyl-(5- to 10-membered heteroaryl (wherein 1-4 heteroaryl members are independently selected from N, O, and S)).

5. The use according to any one of claims 1 to 4, wherein R^3 is optionally substituted -C_1-C_6-alkyl-(5- to 10-membered heteroaryl (wherein 1-4 heteroaryl members are independently selected from N, O, and S)).

6. The use according to any one of claims 1 to 5, wherein R^4 is H.

7. The use according to any one of claims 1 to 6, wherein R^1 is optionally substituted C_6-C_{10}-aryl.

8. The use according to any one of claims 1 to 7, wherein R^1 is optionally substituted phenyl.

9. The use according to any one of claims 1 to 8, wherein R^1 is phenyl.

10. The use according to any one of claims 1 to 9, wherein R^2 is H.

11. The use according to any one of claims 1 to 10, wherein ring A is:



.

12. The use according to any one of claims 1 to 10, wherein ring A is selected from:



and



.

13. The use according to any one of claims 1 to 10, wherein ring A is selected from:



14. The use according to any one of claims 1 to 10, wherein ring  is selected from



15. The use according to claim 1 or 2, wherein:

ring  is ;

R^1 is phenyl or 5- to 6-membered heteroaryl (wherein 1-3 heteroaryl members are independently selected from N, O, and S)), each optionally substituted with one to three substituents independently selected from the group consisting of Br, Cl, F, -CN, C_1-C_6-alkyl, C_1-C_6-haloalkyl, -OC_1-C_6-alkyl, -OC_1-C_6-haloalkyl, optionally substituted phenyl, -C(O)R^A;

R^2 is H;

L is C(O);

R^3 is -C_1-C_6-alkyl-(5- to 7-membered heteroaryl (wherein 1-3 heteroaryl members are independently selected from N, O, and S)) or -C_1-C_6-alkyl(phenyl), wherein heteroaryl or phenyl is optionally substituted with one to three substituents independently selected from the group consisting of Br, Cl, F, C_1-C_6-alkyl, -OC_1-C_6-alkyl, C(O)R^A, and -C(O)N$R^A$$R^B$; and

R^4 is H.

16. The use according to claim 15, wherein:

R^1 is phenyl; and

R^3 is optionally substituted -C_1-C_6-alkyl-(5-membered heteroaryl (wherein 1-2 heteroaryl members are independently selected from N, O, and S)) or optionally substituted C_1-C_6-alkyl(phenyl).

17. The use according to claim 1 or 2, wherein the compound or a tautomer or pharmaceutically acceptable salt thereof is one selected from the following table:

1		**56**	
2		**57**	
3		**58**	
4		**59**	
5		**60**	
6		**61**	
7		**62**	
9		**63**	

10		**64**	
11		**65**	
12		**66**	
13		**67**	
14		**68**	
15		**69**	
16		**70**	
18		**71**	
19		**72**	
20		**73**	
21		**74**	
22		**75**	
24		**76**	

26		**77**	
27		**78**	
28		**79**	
29		**80**	
31		**81**	
32		**82**	
33		**83**	
34		**84**	
35		**85**	
36		**86**	
37		**87**	

38		**88**	
39		**89**	
40		**90**	
41		**91**	
42		**92**	
43		**93**	
44		**94**	
45		**95**	
46		**96**	
47		**97**	

48		**98**	
49		**100**	
50		**101**	
51		**102**	
52		**103**	
53		**104**	
54		**105**	
55		**106**	

18. The use according to claim 1 or 2, wherein the compound or a tautomer or pharmaceutically acceptable salt thereof is one selected from the following table:

107		**133**	

108		**134**	
109		**135**	
110		**136**	
111		**137**	
112		**138**	
113		**139**	
114		**140**	
115		**141**	

116		**142**	
117		**143**	
118		**144**	
119		**145**	
120		**146**	
121		**147**	
122		**148**	

123		**149**	
124		**150**	
125		**151**	
126		**152**	
127		**153**	
128		**154**	
129		**155**	
130		**156**	

131		**157**	
132			

19. The use according to any one of claims 2 to 18, wherein the disease or condition is need for wound repair or need for organ repair.

20. The use according to any one of claims 2 to 18, wherein the disease or condition is selected from the group consisting of a burn, an ulcer, heart failure, and inflammatory bowel disease.

21. The use according to claim 20, wherein disease or condition is a burn.

22. The use according to claim 20, wherein disease or condition is an ulcer.

23. The use according to claim 22, wherein the ulcer is a chronic ulcer.

24. The use according to claim 22 or 23, wherein the ulcer is a diabetic foot ulcer or venous leg ulcer.

25. The use according to any one of claims 2 to 19, wherein the disease or condition is need for wound repair.

26. The use according to any one of claims 2 to 19, wherein the disease or condition is need for organ repair.

27. The use according to claim 26, wherein the organ is selected from the group consisting of a lung, heart, liver, pancreas, liver, and intestine.

28. The use according to any one of claims 2 to 18, wherein the disease or condition is one selected from the group consisting of Diabetic foot ulcer (DFU), Venous Ulcer (Stasis Ulcer), Pressure Ulcers, Full or partial thickness burns, Eczema, Psoriasis, Cellulitis, Impetigo, Atopic dermatitis, Epidermolysis Bullosa, Lichen Sclerosis, Ichthyosis, Vitiligo, Acral peeling skin syndrome, Blau syndrome, Primary cutaneous amyloidosis, Cutaneous abscess, Blepharitis, Furunculosis, Capillaritis, Cellulitis, Corneal Abrasion, Corneal Erosion, Xerosis, Lichen Planus, Lichen Simplex Chronicus, Idiopathic pulmonary fibrosis (IPF), Acute respiratory distress syndrome (ARDS), Chronic Obstructive Pulmonary Disease (COPD), Emphysema, Silicosis, Asbestosis, Pneumoconiosis, Aluminosis, Bauxite fibrosis, Berylliosis, Siderosis, Stannosis, Pulmonary Talcosis, Labrador lung (mixed dust Pneumoconiosis), Sarcoidosis, Hypersensitivity pneumonitis (HP) / extrinsic allergic

alveolitis (EAA), Desquamative interstitial pneumonia (DIP), Respiratory bronchiolitis interstitial lung disease (RBILD), Acute interstitial pneumonia (AIP), Nonspecific interstitial pneumonia (NSIP), Cryptogenic organizing pneumonia (COP = idiopathic BOOP), Secondary organizing pneumonia (BOOP), Lymphoid interstitial pneumonia (LIP), Idiopathic interstitial pneumonia : unspecified, Hypereosinophilic lung diseases, Tuberculosis (TB), Pulmonary Edema, Interstitial Lung Disease, Cryptogenic Organizing Pneumonia (COP), E-cigarette or Vaping Use-Associated Lung Injury (EVALI), Hantavirus Pulmonary Syndrome (HPS), Histoplasmosis, Legionnaires' Disease, MAC Lung Disease, Alpha-1 Antitrypsin Deficiency, Aspergillosis, Lymphangioleiomyomatosis (LAM), Middle Eastern Respiratory Syndrome (MERS), Nontuberculous Mycobacterial Lung Disease (NTM), Pulmonary Embolism Goodpasture syndrome, idiopathic pulmonary hemosiderosis, Alveolar proteinosis, Pulmonary amyloidosis, Primary pulmonary lymphoma, Primary ciliary dyskinesia (without or with situs inversus), Rare cause of hypersensitivity pneumonitis (all causes other than farmer's lung disease and pigeon breeder's lung disease), Pulmonary arteriovenous malformations in hereditary hemorrhagic telangiectasia (HHT), interstitial lung disease in systemic sclerosis, interstitial lung disease in rheumatoid arthritis, interstitial lung disease in idiopathic inflammatory myopathies (polymyositis, dermatomyositis, anti-synthetase syndrome), interstitial lung disease in Sjögren syndrome, interstitial lung disease in mixed connective tissue disease (MCTD), interstitial lung disease in overlap syndromes, interstitial lung disease in undifferentiated connective tissue disease, Bronchiolitis obliterans (in non-transplanted patients), Infectious colitis, Ulcerative colitis , Crohn's disease , Ischemic colitis , Radiation colitis , Peptic ulcer, Intestinal cancer, Intestinal obstruction, Rheumatoid arthritis, Psoriatic arthritis, Hashimoto thyroiditis, Systemic lupus erythematosus, Multiple Sclerosis, Graves' Disease, Type 1 Diabetes Mellitus, Psoriasis, Ankylosing spondylitis, Scleroderma, Myositis, Gout, Antiphospholipid Antibody Syndrome (APS), Vasculitis, Dilated cardiomyopathy, Hypertrophic cardiomyopathy, Restrictive cardiomyopathy, Systolic heart failure, Diastolic heart failure (heart failure with preserved ejection fraction), Atrial Septal Defect, Atrioventricular Septal Defect, Coarctation of the Aorta, Double-outlet Right Ventricle, d-Transposition of the Great Arteries, Ebstein Anomaly, Hypoplastic Left Heart Syndrome, Interrupted Aortic Arch, Pulmonary Atresia, Single Ventricle, Tetralogy of Fallot, Total Anomalous Pulmonary Venous Return, Tricuspid Atresia, Truncus Arteriosus, Ventricular Septal Defect, Polycystic kidney disease, Diabetes

Insipidus , Goodpasture’s Disease, IgA Vasculitis, IgA Nephropathy, Lupus Nephritis, Adult Nephrotic Syndrome, Childhood Nephrotic Syndrome, Hemolytic Uremic Syndrome, Medullary Sponge Kidney, Kidney dysplasia, Renal artery stenosis, Renovascular hypertension, Renal tubular acidosis, Alport syndrome, Wenger’s granulomatosis, Alagille syndrome, Cystinosis, Fabry disease, Focal segmental glomerulosclerosis (FSGS), Glomerulonephritis, aHUS (atypical hemolytic uremic syndrome), Hemolytic uremic syndrome (HUS), Henoch-Schönlein purpura, IgA nephropathy (Berger’s disease), Interstitial nephritis, Minimal change disease, Nephrotic syndrome, Thrombotic thrombocytopenic purpura (TTP), Granulomatosis with polyangiitis (GPA), Adult Still's disease, Agammaglobulinemia, Alopecia areata, Autoimmune angioedema, Autoimmune dysautonomia, Autoimmune encephalomyelitis, Autoimmune hepatitis, Autoimmune myocarditis, Autoimmune oophoritis, Autoimmune orchitis, Autoimmune pancreatitis, Autoimmune retinopathy, Autoimmune urticaria, Axonal & neuronal neuropathy (AMAN), Baló disease, Bullous pemphigoid, Celiac disease, Chronic recurrent multifocal osteomyelitis (CRMO), Churg-Strauss Syndrome (CSS) or Eosinophilic Granulomatosis (EGPA), Cicatricial pemphigoid, Cogan’s syndrome, Cold agglutinin disease, Coxsackie myocarditis, CREST syndrome, Dermatitis herpetiformis, Dermatomyositis, Devic’s disease (neuromyelitis optica), Discoid lupus, Eosinophilic esophagitis (EoE), Eosinophilic fasciitis, Erythema nodosum, Essential mixed cryoglobulinemia, Giant cell arteritis (temporal arteritis), Giant cell myocarditis, Granulomatosis with Polyangiitis, Guillain-Barre syndrome, Hashimoto’s thyroiditis, Henoch-Schonlein purpura (HSP), Herpes gestationis or pemphigoid gestationis (PG), Hypogammalglobulinemia, IgG4-related sclerosing disease, Immune thrombocytopenic purpura (ITP), Inclusion body myositis (IBM), Lambert-Eaton syndrome, Leukocytoclastic vasculitis, Linear IgA disease (LAD), Microscopic polyangiitis (MPA), Mixed connective tissue disease (MCTD), Mooren’s ulcer, Mucha-Habermann disease, Multifocal Motor Neuropathy (MMN) or MMNCB, Multiple sclerosis, Myasthenia gravis, Myositis, Narcolepsy, Neonatal Lupus, Neuromyelitis optica, Neutropenia, Ocular cicatricial pemphigoid, Optic neuritis, Palindromic rheumatism (PR), PANDAS, Paraneoplastic cerebellar degeneration (PCD), Paroxysmal nocturnal hemoglobinuria (PNH), Parry Romberg syndrome, Pars planitis (peripheral uveitis), Parsonage-Turner syndrome, Pemphigus, Peripheral neuropathy, Perivenous encephalomyelitis, Pernicious anemia (PA), POEMS syndrome, Polyarteritis nodosa, Polyglandular syndromes type I, II, III, Polymyalgia rheumatica, Polymyositis, Primary biliary cirrhosis, Primary sclerosing cholangitis, Progesterone dermatitis, Pure red cell aplasia (PRCA), Pyoderma gangrenosum, Raynaud’s

phenomenon, Reactive Arthritis, Reflex sympathetic dystrophy, Relapsing polychondritis, Restless legs syndrome (RLS), Retroperitoneal fibrosis, Rheumatic fever, Rheumatoid arthritis, Sarcoidosis, Schmidt syndrome, Scleritis, Scleroderma, Sjögren's syndrome, Sperm & testicular autoimmunity, Stiff person syndrome (SPS), Subacute bacterial endocarditis (SBE), Susac's syndrome, Sympathetic ophthalmia (SO), Takayasu's arteritis, Temporal arteritis/Giant cell arteritis, Thrombocytopenic purpura (TTP), Thyroid eye disease (TED), Alagille Syndrome, Alcohol-Related Liver Disease, Autoimmune Hepatitis, Biliary Atresia, Cirrhosis, Lysosomal Acid Lipase Deficiency (LAL-D), Newborn Jaundice, Non-Alcoholic Fatty Liver Disease, Non-Alcoholic Steatohepatitis, Primary Biliary Cholangitis (PBC), and Progressive Familial Intrahepatic Cholestasis (PFIC).

29. A compound or a tautomer or pharmaceutically acceptable salt thereof selected from the following table:

1		**56**	
2		**57**	
3		**58**	
4		**59**	
5		**60**	
6		**61**	

7		**62**	
9		**63**	
10		**64**	
11		**65**	
12		**66**	
13		**67**	
14		**68**	
15		**69**	
16		**70**	
18		**71**	
19		**72**	
20		**73**	

21		**74**	
22		**75**	
24		**76**	
26		**77**	
27		**78**	
28		**79**	
29		**80**	
31		**81**	
32		**82**	
33		**83**	
34		**84**	
35		**85**	

36		**86**	
37		**87**	
38		**88**	
39		**89**	
40		**90**	
41		**91**	
42		**92**	
43		**93**	
44		**94**	
45		**95**	

46		**96**	
47		**97**	
48		**98**	
49		**100**	
50		**101**	
51		**102**	
52		**103**	
53		**104**	
54		**105**	
55		**106**	

30. A pharmaceutical composition comprising the compound or a tautomer or pharmaceutically acceptable salt thereof according to claim 29 and a pharmaceutically acceptable carrier.

31. A compound of formula (I), or a tautomer, or a pharmaceutically acceptable salt thereof for use in therapy:


(I)

wherein

ring  is selected from the group consisting of:



R is selected from H and C_1-C_6-alkyl;

R^1 is selected from the group consisting of C_6-C_{10}-aryl, 5- to 10-membered heteroaryl (wherein 1-4 heteroaryl members are independently selected from N, O, and S),

R^2, when present, is selected from the group consisting of H, C_6-C_{10}-aryl, 5- to 10-membered heteroaryl (wherein 1-4 heteroaryl members are independently selected from N, O, and S),

or R^1 and R^2, when bound to adjacent atoms, together with the atoms to which they are bound, form a fused C_6-C_{10}-aryl or 5- to 10-membered heteroaryl (wherein 1-4 heteroaryl members are independently selected from N, O, and S);

L is C(O), C(S), or CH_2;

V is NR^3R^4, wherein

R^3 is selected from the group consisting of C_1-C_6-alkyl, -(C_1-C_6-alkyl)-S-(C_1-C_6-alkyl), -C_1-C_6-alkyl-(C_6-C_{10}-aryl), -C_1-C_6-alkyl-(5- to 10-membered heteroaryl (wherein 1-4 heteroaryl members are independently selected from N, O, and S)), C_3-C_{14}-cycloalkyl, 3- to 14-membered heterocycloalkyl (wherein 1-4 heterocycloalkyl ring members are independently selected from N, O, and S), -C_1-C_6-alkyl-(3- to 14-membered heterocycloalkyl (wherein 1-4 heterocycloalkyl ring members are independently selected from N, O, and S)),

R^4 is selected from the group consisting of H, C_1-C_6-alkyl, -C_1-C_6-alkyl-(C_6-C_{10}-aryl), 5- to 10-membered heteroaryl (wherein 1-4 heteroaryl members are independently selected from N, O, and S);

or R^3 and R^4, together with the N atom to which they are bound, form a 5- to 7-membered heterocycloalkyl optionally fused or spirofused to a (3- to 14-membered heterocycloalkyl (wherein 1-4 heterocycloalkyl ring members are independently selected from N, O, and S);

and wherein any alkyl, aryl, cycloalkyl, heteroaryl, and heterocycloalkyl is optionally substituted by one to four substituents independently selected from the group consisting of -CN, -OH, halo, oxo, -OR^A, -SR^A, -$S(O)R^A$, -$S(O)_2R^A$, NR^AR^B, -$C(O)R^A$, -$C(O)_2R^A$, -$NR^AC(O)_2R^B$, -$C(O)NR^AR^B$, -$S(O)NR^AR^B$, -$S(O)_2NR^AR^B$, -$NR^AS(O)R^B$, -$NR^AS(O)_2R^B$, 5- to 10-membered heteroaryl (wherein 1-4 heteroaryl members are independently selected from N, O, and S;

R^A and R^B are independently selected from the group consisting of H, C_1-C_6-alkyl, C_1-C_6-haloalkyl, -C_1-C_6-alkyl-C_6-C_{10}-aryl, $C(O)C_1$-C_6-alkyl, $C(O)C_1$-C_6-alkyl-C_6-C_{10}-aryl, $C(O)OC_1$-C_6-alkyl, C_6-C_{10}-aryl, 3- to 14-membered heterocycloalkyl (wherein 1-4 heterocycloalkyl ring members are independently selected from N, O, and S), -C(O)(5- to 10-membered heteroaryl (wherein 1-4 heteroaryl members are independently selected from N, O, and S), wherein

each aryl and heterocycloalkyl is optionally substituted with one to three substituents independently selected from C_1-C_6-alkyl, halo, C_1-C_6-haloalkyl, and 3- to 14-membered heterocycloalkyl (wherein 1-4 ring members are independently selected from N, O, and S); and

each alkyl is optionally substituted with one to three substituents independently selected from halo, NR^CR^D (wherein R^C and R^D are independently selected from H, C_1-C_6-alkyl, $C(O)C_1$-C_6-alkyl, and $C(O)C_6$-C_{10}-aryl).